Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Sep 26, 2014; 6(9): 959-967
Published online Sep 26, 2014. doi: 10.4330/wjc.v6.i9.959
Ventricular tachycardia mapping and ablation in arrhythmogenic right ventricular cardiomyopathy/dysplasia: Lessons Learned
Cory M Tschabrunn, Francis E Marchlinski
Cory M Tschabrunn, Harvard-Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States
Francis E Marchlinski, Cardiac Electrophysiology Program, Hospital of the University of Pennsylvania, Philadelphia, PA 19102, United States
Author contributions: Tschabrunn CM wrote the manuscript; Marchlinski FE reviewed and edited the manuscript.
Supported by Research funding from Biosense Webster, Inc., to Marchlinski FE
Correspondence to: Francis E Marchlinski, MD, Cardiac Electrophysiology Program, Hospital of the University of Pennsylvania, Founders 9 Pavilion, Philadelphia, PA 19102, United States. francis.marchlinski@uphs.upenn.edu
Telephone: +1-215-6626005 Fax: +1-215-6622879
Received: January 28, 2014
Revised: June 25, 2014
Accepted: July 12, 2014
Published online: September 26, 2014
Abstract

Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) is primarily believed to be an inherited cardiomyopathy that subsequently results in significant myocardial fibrosis. The arrhythmogenic consequences that result from the development of fibrosis are similar to other nonischemic cardiomyopathies, but the unique endocardial-epicardial disease process of ARVC/D requires a specialized approach for arrhythmia treatment in the electrophysiology laboratory. Although the association between ARVC/D and development of ventricular arrhythmias has become increasingly clear over the last 2 decades, our understanding of the arrhythmia mechanisms, underlying electrophysiologic substrate, and treatment strategies were significantly limited. Prospective studies performed in the electrophysiology laboratory allowed detailed characterization of the electrophysiologic and electroanatomic substrate underlying ventricular tachycardia in patients with ARVC/D. This has allowed clinician scientists to better characterize the arrhythmia mechanism and develop the necessary strategies to perform successful catheter ablation. Early in this experience, catheter ablation was considered a limited and largely unsuccessful treatment for patients experiencing painful and recurrent defibrillator therapy. Through our increased understanding of the disease process, catheter ablation has evolved to become an effective and preferred therapy for a majority of these patients. Our understanding of the disease and necessary approaches to provide successful treatment continues to evolve as the clinical experience grows. This article will review these important insights from the electrophysiology laboratory and how application of this knowledge has facilitated the development of a methodical approach to successfully perform ventricular tachycardia ablation in patients with ARVC/D.

Keywords: Arrhythmogenic right ventricular cardiomyopathy/dysplasia, Ventricular tachycardia, Mapping, Ablation

Core tip: This review article evaluates seminal insights derived from the electrophysiology laboratory and the lessons learned to develop a methodical approach that can utilized to successfully perform ventricular tachycardia ablation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia.